Large Trial Data Link Semaglutide to Lower Risk of Major Adverse Cardiovascular Events

Many women balancing work demands, family needs and their own wellness checks know the quiet worry that comes with heart health. New trial results invite a closer look at one medication's role for those carrying extra weight without diabetes. The SELECT trial found a 20 percent relative risk reduction in major adverse cardiovascular events for adults on semaglutide versus placebo. [1] This adds a fresh layer to earlier data from diabetes-focused studies.

The research followed 17,604 participants over a median of 39.8 months. All had established cardiovascular disease and a BMI of 27 or higher. None had diabetes. Published findings appeared in a major medical journal in late 2023. [1]

What this means

Trial data suggest semaglutide's cardiovascular effects reach adults with overweight or obesity even without type 2 diabetes. Participants on the drug lost about 9.4 percent of their body weight on average. [1] The heart benefits lined up with patterns seen in prior GLP-1 research. That said, exactly how much stems from weight loss versus other actions remains under study.

Key takeaways

• The SELECT trial enrolled 17,604 adults with BMI of 27 or greater, established cardiovascular disease and no diabetes. [2]
• Once-weekly semaglutide 2.4 mg linked to a 20 percent relative risk reduction in MACE (HR 0.80, 95% CI 0.72-0.90, P<0.001). [1]
• An earlier trial in patients with type 2 diabetes reported a 26 percent MACE reduction with semaglutide. [3]
• Benefits appeared consistent with class effects of GLP-1 receptor agonists in high-risk groups. [1][3]
• This marks the first large-scale outcomes trial to test such effects specifically in non-diabetic adults with obesity and preexisting CVD. [2]

The SELECT trial in focus

Researchers ran the SELECT study as a randomized, double-blind, placebo-controlled trial. They gave participants either semaglutide 2.4 mg by weekly injection or a matched placebo. The primary goal centered on time to first major adverse cardiovascular event. That composite included cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.

Comparison to diabetes trials

Earlier evidence came mainly from people already diagnosed with type 2 diabetes. One such study tracked semaglutide and reported a 26 percent drop in the same type of heart events. [3] The newer SELECT results show a 20 percent reduction in a group without diabetes. So the protective signal holds up across both populations.

Secondary findings and weight changes

Mean weight loss reached 9.4 percent in the semaglutide arm. The trial also followed other heart-related measures. Trends favored the treatment group on several secondary outcomes, though the main statistical win came on the primary MACE endpoint. Full details sit in the original report.

Limitations

The evidence does have clear bounds. Researchers enrolled only patients with established atherosclerotic CVD, so primary prevention benefit remains unproven. Demographics skewed toward White and male participants, limiting generalizability to broader populations. Injection-based therapy brings ongoing questions around long-term adherence, cost, gastrointestinal tolerability, and rare events such as gallbladder problems or pancreatitis.

The SELECT trial findings add to the evidence base, but individual care decisions rely on clinical context.